Pharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications
Biomolecules · 2025
DOI: 10.3390/biom15121668 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Ji-Hoon Na und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Republic of Korea. Hauptthemen laut MEDLINE: Cannabidiol, Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cannabidiol (CBD) has transitioned from anecdotal use to an evidence-based adjunctive therapy for Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This review integrates knowledge on CBD’s pharmacology, pharmacokinetics, and clinical implementation, with focus on metabolism, therapeutic drug monitoring (TDM), and clinically relevant interactions with antiseizure medications. CBD exerts CB1/CB2-independent mechanisms—prominently GPR55 antagonism, TRP-channel desensitization, and adenosine-mediated network dampening—supporting efficacy across heterogeneous seizure phenotypes. Its pharmacokinetic profile is characterized by low and variable oral bioavailability, a pronounced food effect, extensive tissue distribution, and phase I/II biotransformation to the active 7-hydroxy-CBD and abundant 7-carboxy-CBD, resulting in substantial inter-individual variability and liability for drug–drug interactions. Clinically salient interactions include CYP2C19-mediated elevation of N-desmethylclobazam and increased transaminases in valproate co-therapy. We summarize emerging TDM practices—standardized fed-state trough sampling with paired measurement of CBD and 7-hydroxy-CBD—and discuss how preliminary interpretive ranges can support dose optimization, adherence assessment, and safety surveillance. Practical recommendations emphasize interaction-aware titration within evidence-based dose bands, liver function monitoring, and standardized documentation of formulation and sampling conditions. Future work should align pharmacogenomics with TDM, refine bioavailability through advanced delivery systems, and tighten analytical and product-quality standards to consolidate CBD as a precision-ready component of modern epilepsy care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Republic of Korea.
ORCID-Profile: Ji-Hoon Na, Young-Mock Lee
Zitieren
APA
Na, J. H., & Lee, Y. M. (2025). Pharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications. Biomolecules. https://doi.org/10.3390/biom15121668
Vancouver
Na JH, Lee YM. Pharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications. Biomolecules. 2025. doi:10.3390/biom15121668
BibTeX
@article{Na2025,
author = {Na, Ji-Hoon and Lee, Young-Mock},
title = {Pharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15121668}
}
EUVIMED